Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Merck
Boehringer Ingelheim
McKinsey
Medtronic

Last Updated: May 23, 2022

CLINICAL TRIALS PROFILE FOR SOLARAZE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Solaraze

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00204542 ↗ Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head Completed University Hospital Tuebingen Phase 4 2005-06-01 Topical treatment of mild to moderate actinic keratosis located on the face and head with Solaraze® is known to be a safe and efficient treatment option. However, it is unclear if an expansion of the treatment period to 6 months will increase the rate of complete responses. Therefore the investigators will evaluate the efficacy and safety of the treatment of actinic keratosis with Solaraze® applied twice daily to the face and head over 3 or 6 months of treatment.
NCT00601640 ↗ Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin Completed National Cancer Institute (NCI) Phase 2 2007-01-01 RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of eflornithine and diclofenac may stop cancer from growing in patients with sun-damaged skin. PURPOSE: This randomized phase II trial is studying the side effects and how well eflornithine works compared with diclofenac, given alone or together, in treating patients with sun-damaged skin.
NCT00601640 ↗ Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin Completed University of Arizona Phase 2 2007-01-01 RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of eflornithine and diclofenac may stop cancer from growing in patients with sun-damaged skin. PURPOSE: This randomized phase II trial is studying the side effects and how well eflornithine works compared with diclofenac, given alone or together, in treating patients with sun-damaged skin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Solaraze

Condition Name

Condition Name for Solaraze
Intervention Trials
Actinic Keratosis 6
Actinic Keratoses 2
Basal Cell Carcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Solaraze
Intervention Trials
Keratosis, Actinic 9
Keratosis 9
Carcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Solaraze

Trials by Country

Trials by Country for Solaraze
Location Trials
United States 47
Germany 6
Austria 2
Netherlands 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Solaraze
Location Trials
Virginia 3
South Carolina 3
Ohio 3
North Carolina 3
Kentucky 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Solaraze

Clinical Trial Phase

Clinical Trial Phase for Solaraze
Clinical Trial Phase Trials
Phase 4 4
Phase 3 4
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Solaraze
Clinical Trial Phase Trials
Completed 10
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Solaraze

Sponsor Name

Sponsor Name for Solaraze
Sponsor Trials
MEDA Pharma GmbH & Co. KG 2
Encube Ethicals Pvt. Ltd. 1
Gesellschaft für Therapieforschung mbH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Solaraze
Sponsor Trials
Industry 10
Other 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Merck
McKinsey
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.